Back to Agenda
European Relative Effectiveness Assessments
Session Chair(s)
Wim Goettsch, PhD, MSc
Special Advisor HTA, Dutch National Health Care Institute (ZIN), Netherlands
Tomas Salmonson, DrMed, PhD
, Critical Path Institute, Netherlands
In the coming years (2016-2020) HTA collaboration in Europe will be intensified in the new EUnetHTA JA3. One of the goals of the EUnetHTA JA3 is facilitate joint assessments of relative effectiveness of pharmaceuticals and to support the use of these joint assessments in national practice. In this panel we will discuss the future of the joint relative effectiveness assessments, their possible use in different types of Member States and the possible alignment of these REAs with the benefit-risk assessments of pharmaceuticals for market authorisation by the EMA.
Speaker(s)
Ioana-Raluca Siska, MD, PhD
Policy Officer, Health Technology Assessment, European Commission, Belgium
EU Cooperation on Health Technology Assessments
Anne D'Andon
Head of Medicines Assessment, Haute Autorité De Santé (HAS), France
Experienced-Based Potentials and Hurdles of European Assessments of Medicines
Tatyana Benisheva, DrMed, MHS, PhD, RAC
President, Bulgarian Association for Drug Information , Bulgaria
Country with Developing HTA Methods
Have an account?